MedPath

Prospective study of predictor for efficiency of treatment with Nintedanib for idiopathic pulmonary fibrosis

Not Applicable
Conditions
idiopathic pulmonary fibrosis
Registration Number
JPRN-UMIN000019751
Lead Sponsor
Kurume University, School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
95
Inclusion Criteria

Not provided

Exclusion Criteria

The patients who fulfilled one of the following criteria 1. Pregnant women. 2. Patient who was determined as ineligible by the investigator or the subinvestigator. 3. Patients treated with the following drug at the start of observation. Corticosteroid (more than 10 mg per day in term of prednizolone) Immunosuppressant N-acetylcysteine Pirfenidone Study drug for idiopathic pulmonary fibrosis 4. Case with exclusion disease

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The correlation between serum periostin level and change of pulmonary function
Secondary Outcome Measures
NameTimeMethod
1. The correlation between serum periostin level and clinical data except for pulmonary function 2. Predictors of overall survival and progression-free-survival
© Copyright 2025. All Rights Reserved by MedPath